Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Philip Ong

Pulmonary Disease San Antonio, TX Medical Doctor

NPI 1093965907 CMS profile 1163269

4502 Medical Dr, San Antonio, TX 78229

Open in the dashboard

General payments

$24,277

116 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Philip Ong of San Antonio, TX is reported in the CMS Open Payments database as having received $24,277 across 116 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $7,256 19
2024 General $6,474 29
2023 General $1,600 12
2022 General $2,289 15
2021 General $1,464 15
2020 General $149 1
2019 General $5,044 25

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Philip Ong
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Philip Ong were reported at $7,256. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Philip Ong Pulmonary Disease median Middle half National median
2019 $5,044 $377 $109–$1,340 $163
2020 $149 $230 $56–$907 $114
2021 $1,464 $269 $68–$1,072 $132
2022 $2,289 $390 $100–$1,457 $149
2023 $1,600 $419 $114–$1,659 $160
2024 $6,474 $476 $123–$1,818 $164
2025 $7,256 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $12,232 40 payments
  2. Pinnacle Biologics, Inc $6,185 25 payments
  3. Pulmonx Corporation $3,137 29 payments
  4. Cook Incorporated $1,820 1 payment
  5. Steris Corporation $233 1 payment
  6. Olympus America Inc. $212 12 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $135 1 payment
  8. Boston Scientific Corporation $110 2 payments
  9. Ethicon Inc. $80 1 payment
  10. Insmed, Inc. $55 1 payment
  11. Other $79 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $9,438 32 payments
  2. Education $6,000 3 payments
  3. Food and Beverage $4,653 76 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,820 3 payments
  5. Consulting Fee $350 1 payment
  6. Gift $15 1 payment
Products named General payments · program years 2019–2025
  1. Da Vinci Surgical System $12,232 40 payments
  2. Photofrin $6,185 25 payments
  3. ZEPHYR ENDOBRONCHIAL VALVE $2,248 22 payments
  4. CHARTIS CATHETER $2,210 21 payments
  5. PULMONX CHARTIS TABLET CONSOLE $2,210 21 payments
  6. ZEPHYR DELIVERY CATHETER $2,210 21 payments
  7. MELKER $1,820 1 payment
  8. Pulmonx Endobronchial Valve EBV $889 7 payments
  9. TruFreeze $233 1 payment
  10. Monarch Platform $80 1 payment
  11. Other $346 16 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

12

Median for Pulmonary Disease: 936

Drug cost

$89

Median for Pulmonary Disease: $487,987

Branded share of claims

0%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Prednisone Generic 12 $89

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 32 billing codes

Paid by Medicare

$25,826

Medicare's payments for the services billed

Medicare patients

94

Average age 70

Services billed

330

41 women, 53 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
COPD 63%
Chronic kidney disease 50%
Arthritis 45%
Diabetes 40%
Ischemic heart disease 39%
Depression 32%
Osteoporosis 32%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

116 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record